Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: A population based case-control study from western Norway

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 4, 1998, Pages 539-542

  Myhr, Kjell Morten ^a   Riise, Trond ^a   Barrett Connor, Elizabeth ^b   Myrmel, Helge ^a   Vedeler, Christian ^a   Grønning, Marit ^a   Kalvenes, May Britt ^a   Nyland, Harald ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Epstein Barr virus; Herpesvirus; Multiple sclerosis

Indexed keywords

CELL NUCLEUS ANTIGEN; EARLY ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS CAPSID ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HERPES SIMPLEX VIRUS; HERPES VIRUS; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NORWAY; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

EID: 0031967440     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.4.539     Document Type: Article

References (30)

1. Cook SD, Rohowsky-Kochan S, Bansil S, et al. Evidence for multiple sclerosis as an infectious disease. Acta Neurol Scan Suppl 1995;161:34-42.
2. Miller G. Epstein-Barr virus; biology, pathogenesis and medical aspects. In: Fields BN, Knipe DM, Chanock RM, et al, eds. Fields virology. New York.Raven 1990:1921-58.
3. Silverstein A, Steinberg G, Nathanson M. Nervous system involvment in infectious mononucleosis. Arch Neurol 1972: 26:353-8.
4. Bray PF, Culp KW, McFarlin DE, et al. Demyelinating disease after neurologically complicated primary Epstein-Barr virus infection. Neurology 1992;42:278-82.
5. Operskalski EA, Visscher BR, Malmgren RM, et al. A case-control study of multiple sclerosis. Neurology 1989;39: 825-9.
6. Lindberg C, Andersen O, Vahine A, et al. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiol 1991;10: 62-5.
7. Martyn CN, Cruddas M, Compston DA. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 1993;56:167-8.
8. Haahr S, Koch-Henriksen N, Møller-Larsen A, et al. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Multiple Sclerosis 1995;1:1-5.
9. Evans AS, Niederman JC. Epstein-Barr virus. In: Evans AS, ed. Viral infections of humans: epidemiology and control. New York: Plenum Medical Books 1989:265-92.
10. Alter M, Leibowitz U, Speer J. Risk of multiple sclerosis related to age at immigration to Israel. Arch Neurol 1966;15:234-7.
11. Alter M, Okihiro M. When is multiple sclerosis acquired? Neurology 1971;21:1030-6.
12. Elian M, Nightingale S, Dean G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa, and the West Indies. J Neurol Neurosurg Psychiatry 1990;53:906-11.
13. Sumaya CV, Myers LW, Ellison GW. Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol 1980;37: 94-6.
14. Bray PF, Bloomer LC, Salmon VC, et al. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 1983;40:406-8.
15. Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985;35:435-8.
16. Sumaya CV, Myers LW, Ellison GW, et al. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 1985;17: 371-7.
17. Shirodaria PV, Haire M, Fleming E, et al. Viral antibody titers. Comparison in patients with multiple sclerosis and rheumatoid arthritis. Arch Neurol 1987;44:1237-41.
18. Compston DA, Vakarelis BN, Paul E, et al. Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 1986;109:325-14.
19. Coyle PK, Sibony PA. Viral specificity of multiple sclerosis tear immunoglobulins. J Neuroimmunol 1987;14:197-203.
20. Vaughan JH, Riise T, Rhodes GH, et al. An Epstein-Barr virus related cross reactive autoimmune response in multiple sclerosis in Norway. J Neuroimmunol 1996;69:95-102.
21. Riise T, Gronning M, Klauber MR, et al. Clustering of residence of multiple sclerosis patients at age 13 to 20 years in Hordaland, Norway. Am J Epidemiol 1991;133: 932-9.
22. McAlpine D. The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 1961;84:186-203.
23. Kinnunen E, Valle M, Piirainen L, et al. Viral antibodies in multiple sclerosis. A nationwide co-twin study. Arch Neurol 1990;47:743-6.
24. Felgenhauer K, Schadlich HJ, Nekic M, et al. Cerebrospinal fluid virus antibodies. A diagnostic indicator for multiple sclerosis. J Neurol Sci 1985;71:291-9.
25. Antel J, Arnason BGW, Medof ME. Supressor cell function in multiple sclerosis correlation with clinical disease activity. Ann Neurol 1979;5:338-42.
26. Craig JC, Haire M, Millar JH, et al. Immunological control of Epstein-Barr virus-transformed lymphocytes in multiple sclerosis. Clin Immunol Immunopathol 1983;29:86-93.
27. Hilton DA, Love S, Fletcher A, et al. Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridisation. J Neurol Neurosurg Psychiatry 1994;57:975-6.
28. Jahnke U, Fischer EH, Alvord EC Jr. Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis. Science 1985;229:282-4.
29. Bray PF, Luka J, Bray PF, et al. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992;42:1798-804.
30. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.